MetasTx LLC is a technology company.
MetasTx LLC has raised $100K across 1 funding round.
MetasTx LLC has raised $100K in total across 1 funding round.
MetasTx LLC has raised $100K in total across 1 funding round.
MetasTx LLC's investors include Innovation Works.
MetasTx LLC is a pharmaceutical company specializing in developing novel therapeutics to prevent and treat cancer metastasis, with a particular focus on prostate cancer. Their product pipeline includes next-generation inhibitors targeting Group-1 P21 activated kinases (PAK), which play a key role in the metastatic process of solid tumors such as prostate, breast, and skin cancers. MetasTx aims to create a precision oncology platform that pairs validated companion diagnostics with targeted therapies to prevent metastasis before it starts, thereby improving patient outcomes and reducing unnecessary side effects[1][3][4].
The company serves patients at high risk of cancer metastasis, oncologists, and the broader oncology community by addressing the critical unmet need of stopping cancer spread early. MetasTx is gaining momentum through ongoing National Cancer Institute-supported diagnostic studies and advancing drug candidates toward investigational new drug (IND) enabling studies, positioning itself at an inflection point in oncology innovation[3].
Founded in 2021 and headquartered in Pittsburgh, Pennsylvania, MetasTx was co-founded by Harvey D. Homan, Ph.D., MBA, a biotech executive with a background in neuropharmacology and business leadership. The company’s scientific foundation builds on decades of research into PAK-1, a kinase implicated in cancer metastasis, with significant contributions from academic labs such as the Crich UGARF labs. The idea emerged from the need to develop therapies that specifically target the epithelial-mesenchymal transition (EMT) process critical to metastasis. Early traction includes securing support from incubators like AlphaLab Health and Innovation Works, raising initial funding of $50K, and recruiting renowned cancer scientists like Dr. Jonathan Chernoff to its scientific advisory board[1][2][3].
MetasTx is riding the growing trend of precision oncology and targeted cancer therapies, focusing on metastasis prevention—a critical unmet need in cancer treatment. The timing is favorable due to advances in molecular diagnostics, increased understanding of metastatic mechanisms, and rising demand for therapies that improve survival and quality of life. Market forces such as increasing cancer incidence, especially prostate cancer, and supportive funding from institutions like the National Cancer Institute create a conducive environment for MetasTx’s growth. By developing therapies that intervene early in the metastatic cascade, MetasTx influences the broader oncology ecosystem by potentially shifting treatment paradigms from reactive to proactive management of cancer spread[3][4].
Looking ahead, MetasTx is positioned to advance its lead candidates through IND-enabling studies and clinical trials, supported by ongoing diagnostic validation. Trends shaping their journey include the integration of companion diagnostics with therapeutics, growing emphasis on metastasis prevention, and personalized medicine approaches. As MetasTx progresses, its influence may expand beyond prostate cancer to other solid tumors, potentially transforming how metastasis is managed and improving long-term patient outcomes. Their capital-efficient, science-driven approach suggests a promising trajectory in the competitive oncology therapeutics landscape[3].
This focus on preventing cancer metastasis before it starts encapsulates MetasTx’s mission to change the story of cancer for good.
MetasTx LLC has raised $100K across 1 funding round. Most recently, it raised $100K Seed in December 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2023 | $100K Seed | Innovation Works |